http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105579452-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-002 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
| filingDate | 2014-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105579452-B |
| titleOfInvention | Novel 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors |
| abstract | The present invention relates to pharmaceutical agents useful for the treatment and/or prophylaxis in mammals, and in particular to inhibitors of NF-κB-induced kinase (NIK-also known as MAP3K14), which are useful in the treatment of , such as: cancer, inflammatory disorders, metabolic disorders, and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds; to methods of preparing such compounds and compositions; and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders , metabolic disorders including obesity and diabetes, and autoimmune disorders. |
| priorityDate | 2013-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 420.